Proof-of-Concept Study Shows an HIV Vaccine Can Generate Key Antibody Response in People

National Institute of Allergy and Infectious Diseases sent this bulletin at 05/20/2024 04:56 PM EDT

Monday, May 20, 2024

Proof-of-Concept Study Shows an HIV Vaccine Can Generate Key Antibody Response in People

Several small spheres surrounded by irregular matter.

Colorized transmission electron micrograph of HIV-1 virus particles (orange) budding and replicating from an H9 T cell (teal). The virus particles are in various stages of maturity, which accounts for differences in shape. Captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID

An HIV vaccine candidate elicited trace levels of HIV broadly neutralizing antibodies and high levels of other key immune cells in an early-stage clinical trial. This immune response is an important signal that, if antibody levels can be further amplified, the vaccination strategy might be able to prevent HIV. The findings of this NIAID-supported trial were published in the journal Cell.

Learn More

National Institute of Allergy and Infectious Diseases | National Institutes of Health

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period.

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).